Skip to main content
Top
Published in: Gastric Cancer 2/2016

01-04-2016 | Original Article

Second primary malignancy risk among patients with gastric cancer: a nationwide population-based study in Taiwan

Authors: San-Chi Chen, Chia-Jen Liu, Yu-Wen Hu, Chiu-Mei Yeh, Li-Yu Hu, Yen-Po Wang, Yi-Ping Hung, Cheng-Hwai Tzeng, Tzeon-Jye Chiou, Tzeng-Ji Chen, Chung-Jen Teng

Published in: Gastric Cancer | Issue 2/2016

Login to get access

Abstract

Background

Several studies have reported an increase in second primary malignancies (SPMs) among gastric cancer patients.

Methods

Patients who were newly diagnosed with gastric cancer between 1997 and 2011 were recruited from the Taiwan National Health Insurance database. Those who had antecedent malignancies or gastrointestinal stromal tumor were excluded. Standardized incidence ratios (SIRs) of SPMs were calculated. Risk factors for cancer development were analyzed by Cox proportional hazards models. Effects of treatments for gastric cancer were treated as time-dependent variables.

Results

During the 15-year study period, 47,729 gastric cancer patients were recruited. Overall, 2,110 SPMs developed during a total follow-up of 137,798 person-years. The SIR for all cancers was 1.46. The SIRs for specific follow-up periods were 1.43, 1.41, and 1.21 at >10 years, 5–10 years, and 1–5 years, respectively. After excluding SPMs that developed within 1 year, significantly higher SIRs were seen for cancers of the head and neck (1.34), esophagus (2.16), colon and rectum (1.37), bones and soft tissues (1.95), ovaries (2.89), bladder (1.47), or kidneys (1.44), as well as non-Hodgkin’s lymphoma (5.56). Multivariate analysis showed that age ≥70 years [hazard ratio (HR) 1.19], being male (HR 1.37), diabetes mellitus (HR 1.30), chronic obstructive pulmonary disease (HR 1.17), and liver cirrhosis (HR 1.94) were independent risk factors. Radiotherapy (HR 1.24) and chemotherapy (HR 1.87) were independent risk factors, but surgery (HR 0.67) was not.

Conclusions

Patients with gastric cancer are at increased risk of developing SPM. Close surveillance of patients with risk factors over a longer period should be considered.
Literature
1.
go back to reference Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
2.
go back to reference Chen CJ, You SL, Lin LH, Hsu WL, Yang YW. Cancer epidemiology and control in Taiwan: a brief review. Jpn J Clin Oncol. 2002;32(Suppl):S66–81.CrossRefPubMed Chen CJ, You SL, Lin LH, Hsu WL, Yang YW. Cancer epidemiology and control in Taiwan: a brief review. Jpn J Clin Oncol. 2002;32(Suppl):S66–81.CrossRefPubMed
3.
go back to reference Tanaka K, Kiyohara Y, Kubo M, et al. Secular trends in the incidence, mortality, and survival rate of gastric cancer in a general Japanese population: the Hisayama study. Cancer Causes Control. 2005;16:573–8.CrossRefPubMed Tanaka K, Kiyohara Y, Kubo M, et al. Secular trends in the incidence, mortality, and survival rate of gastric cancer in a general Japanese population: the Hisayama study. Cancer Causes Control. 2005;16:573–8.CrossRefPubMed
4.
5.
go back to reference Wu CY, Wu MS, Kuo KN, Wang CB, Chen YJ, Lin JT. Effective reduction of gastric cancer risk with regular use of nonsteroidal anti-inflammatory drugs in Helicobacter pylori-infected patients. J Clin Oncol. 2010;28:2952–7.CrossRefPubMed Wu CY, Wu MS, Kuo KN, Wang CB, Chen YJ, Lin JT. Effective reduction of gastric cancer risk with regular use of nonsteroidal anti-inflammatory drugs in Helicobacter pylori-infected patients. J Clin Oncol. 2010;28:2952–7.CrossRefPubMed
6.
go back to reference Otsuji E, Yamaguchi T, Sawai K, Hagiwara A, Taniguchi H, Takahashi T. Recent advances in surgical treatment have improved the survival of patients with gastric carcinoma. Cancer. 1998;82:1233–7.CrossRefPubMed Otsuji E, Yamaguchi T, Sawai K, Hagiwara A, Taniguchi H, Takahashi T. Recent advances in surgical treatment have improved the survival of patients with gastric carcinoma. Cancer. 1998;82:1233–7.CrossRefPubMed
8.
go back to reference Yoshino K, Asanuma F, Hanatani Y, Otani Y, Kumai K, Ishibiki K. Multiple primary cancers in the stomach and another organ: frequency and the effects on prognosis. Jpn J Clin Oncol. 1985;15(Suppl 1):183–90.PubMed Yoshino K, Asanuma F, Hanatani Y, Otani Y, Kumai K, Ishibiki K. Multiple primary cancers in the stomach and another organ: frequency and the effects on prognosis. Jpn J Clin Oncol. 1985;15(Suppl 1):183–90.PubMed
9.
go back to reference Kim C, Chon HJ, Kang B, et al. Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer. BMC Cancer. 2013;13:394.CrossRefPubMedPubMedCentral Kim C, Chon HJ, Kang B, et al. Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer. BMC Cancer. 2013;13:394.CrossRefPubMedPubMedCentral
10.
go back to reference Eom BW, Lee HJ, Yoo MW, et al. Synchronous and metachronous cancers in patients with gastric cancer. J Surg Oncol. 2008;98:106–10.CrossRefPubMed Eom BW, Lee HJ, Yoo MW, et al. Synchronous and metachronous cancers in patients with gastric cancer. J Surg Oncol. 2008;98:106–10.CrossRefPubMed
11.
go back to reference Ha TK, An JY, Youn HG, Noh JH, Sohn TS, Kim S. Surgical outcome of synchronous second primary cancer in patients with gastric cancer. Yonsei Med J. 2007;48:981–7.CrossRefPubMedPubMedCentral Ha TK, An JY, Youn HG, Noh JH, Sohn TS, Kim S. Surgical outcome of synchronous second primary cancer in patients with gastric cancer. Yonsei Med J. 2007;48:981–7.CrossRefPubMedPubMedCentral
12.
go back to reference Hiyama T, Hanai A, Fujimoto I. Second primary cancer after diagnosis of stomach cancer in Osaka, Japan. Jpn J Cancer Res. 1991;82:762–70.CrossRefPubMed Hiyama T, Hanai A, Fujimoto I. Second primary cancer after diagnosis of stomach cancer in Osaka, Japan. Jpn J Cancer Res. 1991;82:762–70.CrossRefPubMed
13.
go back to reference Hirono M, Niimoto M, Toge T, et al. A cohort study on second malignancies in gastrectomized patients with gastric cancer. II. Second malignancies in the gastric remnant. Jpn J Surg. 1986;16:344–50.CrossRefPubMed Hirono M, Niimoto M, Toge T, et al. A cohort study on second malignancies in gastrectomized patients with gastric cancer. II. Second malignancies in the gastric remnant. Jpn J Surg. 1986;16:344–50.CrossRefPubMed
14.
go back to reference Lundegardh G, Hansson LE, Nyren O, Adami HO, Krusemo UB. The risk of gastrointestinal and other primary malignant diseases following gastric cancer. Acta Oncol. 1991;30:1–6.CrossRefPubMed Lundegardh G, Hansson LE, Nyren O, Adami HO, Krusemo UB. The risk of gastrointestinal and other primary malignant diseases following gastric cancer. Acta Oncol. 1991;30:1–6.CrossRefPubMed
15.
go back to reference Cheng TM. Taiwan’s new national health insurance program: genesis and experience so far. Health Aff (Millwood). 2003;22:61–76.CrossRefPubMed Cheng TM. Taiwan’s new national health insurance program: genesis and experience so far. Health Aff (Millwood). 2003;22:61–76.CrossRefPubMed
16.
go back to reference Wu CW, Lo SS, Chen JH, Hsieh MC, Li AF, Lui WY. Multiple primary cancers in patients with gastric cancer. Hepatogastroenterology. 2006;53:463–7.PubMed Wu CW, Lo SS, Chen JH, Hsieh MC, Li AF, Lui WY. Multiple primary cancers in patients with gastric cancer. Hepatogastroenterology. 2006;53:463–7.PubMed
17.
go back to reference Park YK, Kim DY, Joo JK, et al. Clinicopathological features of gastric carcinoma patients with other primary carcinomas. Langenbecks Arch Surg. 2005;390:300–5.CrossRefPubMed Park YK, Kim DY, Joo JK, et al. Clinicopathological features of gastric carcinoma patients with other primary carcinomas. Langenbecks Arch Surg. 2005;390:300–5.CrossRefPubMed
18.
go back to reference Ikeda Y, Saku M, Kawanaka H, Nonaka M, Yoshida K. Features of second primary cancer in patients with gastric cancer. Oncology. 2003;65:113–7.CrossRefPubMed Ikeda Y, Saku M, Kawanaka H, Nonaka M, Yoshida K. Features of second primary cancer in patients with gastric cancer. Oncology. 2003;65:113–7.CrossRefPubMed
19.
go back to reference Dinis-Ribeiro M, Lomba-Viana H, Silva R, Moreira-Dias L, Lomba-Viana R. Associated primary tumors in patients with gastric cancer. J Clin Gastroenterol. 2002;34:533–5.CrossRefPubMed Dinis-Ribeiro M, Lomba-Viana H, Silva R, Moreira-Dias L, Lomba-Viana R. Associated primary tumors in patients with gastric cancer. J Clin Gastroenterol. 2002;34:533–5.CrossRefPubMed
20.
21.
go back to reference Bozzetti F, Bonfanti G, Mariani L, Miceli R, Andreola S. Risk of second malignancies after surgical treatment for early gastric cancer. Gastric Cancer. 1999;2:74–5.CrossRefPubMed Bozzetti F, Bonfanti G, Mariani L, Miceli R, Andreola S. Risk of second malignancies after surgical treatment for early gastric cancer. Gastric Cancer. 1999;2:74–5.CrossRefPubMed
22.
go back to reference Ikeda Y, Saku M, Kishihara F, Maehara Y. Effective follow-up for recurrence or a second primary cancer in patients with early gastric cancer. Br J Surg. 2005;92:235–9.CrossRefPubMed Ikeda Y, Saku M, Kishihara F, Maehara Y. Effective follow-up for recurrence or a second primary cancer in patients with early gastric cancer. Br J Surg. 2005;92:235–9.CrossRefPubMed
23.
go back to reference Curtis RE FD, Ron E, Ries LAG, Hacker DG, Edwards BK, Tucker MA, Fraumeni JF Jr. (eds). New malignancies among cancer survivors: SEER cancer registries, 1973–2000. NIH publ. no. 05-5302. Bethesda: National Cancer Institute; 2006. Curtis RE FD, Ron E, Ries LAG, Hacker DG, Edwards BK, Tucker MA, Fraumeni JF Jr. (eds). New malignancies among cancer survivors: SEER cancer registries, 1973–2000. NIH publ. no. 05-5302. Bethesda: National Cancer Institute; 2006.
24.
25.
go back to reference Williams CN. Helicobacter pylori, gastric cancer and gastric MALT lymphoma. Can J Gastroenterol. 1996;10:359–60.PubMed Williams CN. Helicobacter pylori, gastric cancer and gastric MALT lymphoma. Can J Gastroenterol. 1996;10:359–60.PubMed
26.
go back to reference Krishnan B, Morgan GJ. Non-Hodgkin lymphoma secondary to cancer chemotherapy. Cancer Epidemiol Biomark Prev. 2007;16:377–80.CrossRef Krishnan B, Morgan GJ. Non-Hodgkin lymphoma secondary to cancer chemotherapy. Cancer Epidemiol Biomark Prev. 2007;16:377–80.CrossRef
27.
go back to reference Mauch PM, Kalish LA, Marcus KC, et al. Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin’s disease: long-term analysis of risk factors and outcome. Blood. 1996;87:3625–32.PubMed Mauch PM, Kalish LA, Marcus KC, et al. Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin’s disease: long-term analysis of risk factors and outcome. Blood. 1996;87:3625–32.PubMed
28.
go back to reference Menu-Branthomme A, Rubino C, Shamsaldin A, et al. Radiation dose, chemotherapy and risk of soft tissue sarcoma after solid tumours during childhood. Int J Cancer. 2004;110:87–93.CrossRefPubMed Menu-Branthomme A, Rubino C, Shamsaldin A, et al. Radiation dose, chemotherapy and risk of soft tissue sarcoma after solid tumours during childhood. Int J Cancer. 2004;110:87–93.CrossRefPubMed
29.
go back to reference Tucker MA, D’Angio GJ, Boice JD Jr, et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med. 1987;317:588–93.CrossRefPubMed Tucker MA, D’Angio GJ, Boice JD Jr, et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med. 1987;317:588–93.CrossRefPubMed
30.
go back to reference Wong FL, Boice JD Jr, Abramson DH, et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA. 1997;278:1262–7.CrossRefPubMed Wong FL, Boice JD Jr, Abramson DH, et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA. 1997;278:1262–7.CrossRefPubMed
31.
go back to reference Henderson TO, Rajaraman P, Stovall M, et al. Risk factors associated with secondary sarcomas in childhood cancer survivors: a report from the childhood cancer survivor study. Int J Radiat Oncol Biol Phys. 2012;84:224–30.CrossRefPubMedPubMedCentral Henderson TO, Rajaraman P, Stovall M, et al. Risk factors associated with secondary sarcomas in childhood cancer survivors: a report from the childhood cancer survivor study. Int J Radiat Oncol Biol Phys. 2012;84:224–30.CrossRefPubMedPubMedCentral
32.
go back to reference Lo SF, Chang SN, Muo CH, et al. Modest increase in risk of specific types of cancer types in type 2 diabetes mellitus patients. Int J Cancer. 2013;132:182–8.CrossRefPubMed Lo SF, Chang SN, Muo CH, et al. Modest increase in risk of specific types of cancer types in type 2 diabetes mellitus patients. Int J Cancer. 2013;132:182–8.CrossRefPubMed
33.
go back to reference Kalaitzakis E, Gunnarsdottir SA, Josefsson A, Bjornsson E. Increased risk for malignant neoplasms among patients with cirrhosis. Clin Gastroenterol Hepatol. 2011;9:168–74.CrossRefPubMed Kalaitzakis E, Gunnarsdottir SA, Josefsson A, Bjornsson E. Increased risk for malignant neoplasms among patients with cirrhosis. Clin Gastroenterol Hepatol. 2011;9:168–74.CrossRefPubMed
34.
go back to reference Kornum JB, Svaerke C, Thomsen RW, Lange P, Sorensen HT. Chronic obstructive pulmonary disease and cancer risk: a Danish nationwide cohort study. Respir Med. 2012;106:845–52.CrossRefPubMed Kornum JB, Svaerke C, Thomsen RW, Lange P, Sorensen HT. Chronic obstructive pulmonary disease and cancer risk: a Danish nationwide cohort study. Respir Med. 2012;106:845–52.CrossRefPubMed
35.
go back to reference Takekuni K, Furukawa H, Tsukuma H, et al. The risk of second malignancy after adjuvant chemotherapy for stomach cancer. Gastric Cancer. 1999;2:206–9.CrossRefPubMed Takekuni K, Furukawa H, Tsukuma H, et al. The risk of second malignancy after adjuvant chemotherapy for stomach cancer. Gastric Cancer. 1999;2:206–9.CrossRefPubMed
36.
go back to reference Kinoshita Y, Tsukuma H, Ajiki W, et al. The risk for second primaries in gastric cancer patients: adjuvant therapy and habitual smoking and drinking. J Epidemiol. 2000;10:300–4.CrossRefPubMed Kinoshita Y, Tsukuma H, Ajiki W, et al. The risk for second primaries in gastric cancer patients: adjuvant therapy and habitual smoking and drinking. J Epidemiol. 2000;10:300–4.CrossRefPubMed
37.
go back to reference Nio Y, Hirahara N, Minari Y, et al. Second malignancies after a gastrectomy for gastric cancers: the effects of adjuvant therapies. Anticancer Res. 1999;19:3591–9.PubMed Nio Y, Hirahara N, Minari Y, et al. Second malignancies after a gastrectomy for gastric cancers: the effects of adjuvant therapies. Anticancer Res. 1999;19:3591–9.PubMed
Metadata
Title
Second primary malignancy risk among patients with gastric cancer: a nationwide population-based study in Taiwan
Authors
San-Chi Chen
Chia-Jen Liu
Yu-Wen Hu
Chiu-Mei Yeh
Li-Yu Hu
Yen-Po Wang
Yi-Ping Hung
Cheng-Hwai Tzeng
Tzeon-Jye Chiou
Tzeng-Ji Chen
Chung-Jen Teng
Publication date
01-04-2016
Publisher
Springer Japan
Published in
Gastric Cancer / Issue 2/2016
Print ISSN: 1436-3291
Electronic ISSN: 1436-3305
DOI
https://doi.org/10.1007/s10120-015-0482-3

Other articles of this Issue 2/2016

Gastric Cancer 2/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine